APPLIED GENETIC TECHNOLOGIES CORP
DelistedCIK 1273636fmd_1BDZRMWRBQDEMXR04S3VJVVEF8Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jul 01, 2011 to Sep 30, 2022, 42 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 1 | 2 | 47 | 39 | 24 | 42 | 2 | 1 | 0 |
| Research and development | 3 | 9 | 18 | 39 | 26 | 32 | 33 | 36 | 44 | 50 |
| Total operating expenses | 5 | 14 | 27 | 49 | 38 | 47 | 46 | 49 | 59 | 67 |
| Operating income | (4) | (13) | (25) | (2) | 2 | (22) | (4) | (47) | (58) | (66) |
| Interest expense | 0 | – | – | – | – | – | – | 0 | 2 | 3 |
| Interest and investment income | 0 | 0 | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (1) | (3) | 0 | 1 | 1 | 1 | 2 | 1 | (1) | (3) |
| Income before taxes | – | – | (24) | (1) | 3 | (21) | (2) | (46) | (60) | (69) |
| Income tax expense | – | – | – | – | 2 | 0 | 0 | 0 | (2) | 0 |
| Net income from continuing operations | – | – | – | – | 0 | (21) | (2) | (46) | (58) | (69) |
| Net income | (5) | (16) | (24) | (1) | 0 | (21) | (2) | (46) | (58) | (69) |